Schizophrenia is a devastating neurodevelopmental disorder whose genetic influences remain elusive. We hypothesize that individually rare structural variants contribute to the illness. Microdeletions and microduplications >100kb were identified by microarray comparative genomic hybridization (CGH) of genomic DNA from 150 individuals with schizophrenia and 268 ancestry-matched controls. All variants were validated by high-resolution platforms. Novel deletions and duplications of genes were present in 5% of controls versus 15% of cases (P = 0.0008) and 20% of young onset cases (P = 0.0001). The association was independently replicated in patients with childhood-onset schizophrenia compared to their parents (P = 0.03). Mutations in cases disrupted genes disproportionately from signaling networks controlling neurodevelopment, including neuregulin and glutamate pathways. These results suggest that multiple, individually rare mutations impacting genes in neurodevelopmental pathways contribute to schizophrenia.
environmental exposures likely involved. Family, twin and adoption studies all support a strong genetic influence, although patterns of inheritance are variable and not consistent with a single monogenic Mendelian trait (1) .
The present working hypothesis for genetic influences on schizophrenia is the "common disease-common allele" model (2) ; that is, that the illness is caused by combinations of common alleles, each contributing a modest effect. We propose an alternative model: that some mutations predisposing to schizophrenia are highly penetrant, individually rare, and of recent origin, even specific to single cases or families (3) .
Genomic microduplications and microdeletions, also known as structural variants or copy number variants, underlie many serious illnesses, including neurological and neurodevelopmental syndromes (4) . Previously we found a significantly increased frequency of de novo deletions and duplications in children with autism spectrum disorders (5), suggesting that rare structural variants collectively account for a larger proportion of these disorders than previously recognized. Direct methods for detection of microdeletions and microduplications can be used for gene discovery in other psychiatric disorders as well.
The hypothesis that chromosomal mutations may cause schizophrenia is not new. Karyotypic abnormalities have been detected in affected individuals or families (6) , including events that led to the discovery of potential disease-causing mutations in DISC1 (7), PDE4B (7) and NPAS3 (8) . Deletions at 22q11.2 are also associated with schizophrenia (9) . However, the ability to detect structural mutations associated with schizophrenia was historically limited to large events identifiable by karyotype. The development of microarray-based methods now enables the detection of much smaller events. Using these methods, structural mutations involving genes in neurodevelopmental pathways have been identified in individuals with schizophrenia, including a deletion disrupting NRXN1 in affected siblings (10), a de novo duplication involving APBA2 in one patient (10) , and deletions containing CNTNAP2 in two unrelated patients (11) .
If severe mutations leading to schizophrenia are individually rare, then each individual mutation will explain only a small number of patients, or even only one patient. The overall involvement of rare mutations in the illness can be tested statistically by comparing the collective frequency of rare variants in cases to their collective frequency among controls. Here, we examine whether rare structural mutations throughout the genome are more frequent among persons with schizophrenia than among unaffected individuals. We then examine whether genes disrupted by structural mutations in cases are more likely than genes disrupted in controls to encode proteins critical to brain development.
Genome-wide scans for structural variants greater than 100kb were carried out on genomic DNA of 418 individuals, including 150 persons with schizophrenia or schizoaffective disorder meeting DSM-IV criteria and 268 healthy individuals (controls) age 35 or older who were free of signs of neurological or psychiatric illness. Detailed clinical information regarding the cases is provided in the supplementary materials [(12) and table S1]. Distributions of racial ancestries were the same in cases and controls. ROMA 85K probe microarrays were used for event discovery. Illumina 550K microarrays and NimbleGen 2.1M feature HD2 microarrays were used to validate events and refine genomic breakpoints (12) . Stringent quality control criteria were applied to microarray data to obtain reliable measures of intensity, to exclude false positives, and to ensure that ascertainment of structural variants was consistent between cases and controls (12) . First, frequencies in cases versus controls were compared for the 115 common variants (i.e. with frequency >1%) that passed our quality criteria and were verified by an independent method. Frequencies of these common variants did not differ between cases and controls ( fig. S1 ). Second, detection sensitivity of rare variants was measured by simulating structural variants of various sizes at many different genomic locales and screening for them in blind tests. Detection sensitivity varied by event size and locale but was the same in cases and controls ( fig. S2 ).
Variants ultimately included in this study passed all these quality control tests [see also (12) ] and met our criteria for rare variants, defined as those not previously described in the published literature or on the Database of Genomic Variants, version 3, November 29, 2007 update (13) . In the 418 cases and controls, we identified and validated 53 previously unreported microdeletions and microduplications, of sizes ranging from 100kb to 15 MB.
Individuals with schizophrenia were >3-fold more likely than controls to harbor rare structural variants that deleted or duplicated one or more genes ( Table 1 , P = 0.0008). Cases with onset of psychotic symptoms at age 18 years or younger were >4-fold more likely than controls to harbor such variants ( Table 1 , P = 0.0001). In contrast, there was no significant difference in the proportions of cases versus controls carrying rare mutations that did not impact any genes (table S2) .
We tested the same hypothesis in an independent series of cases and controls, using a rigorously characterized cohort of youth with childhood onset schizophrenia (COS). COS is a rare and typically more severe form of the illness (14) . Of the 92 patients in this cohort, nine patients known to harbor major chromosomal abnormalities (15) (16) (17) were excluded from this analysis, leaving 83 individuals. Given the heterogeneous ancestries of the COS patients, we evaluated the non-transmitted chromosomes of available parents (N = 154) as controls. Parental relationships were validated using multiple polymorphic markers. Because each parent contributed one haploid non-transmitted genome to analysis, the effective diploid sample size of our control group was 154/2 or 77. Genome-wide scans for structural variants >100kb and >20 SNPs were carried out on genomic DNA from COS cases and their parents by Affymetrix 500K SNP Arrays (NspI and StyI chips). All events were validated by Agilent 185K or 244K ArrayCGH and by custom BAC arrays targeting genomic regions of segmental duplications (18) . Rare variants were defined as for the original series. Insofar as possible, genotypes from parents were used to determine if variants were de novo or inherited.
In the COS cases, we identified and validated 27 previously unreported deletions and duplications in 23 individuals. A 2.5 MB deletion on chromosome 2q31.2-q31.3 and a 183kb duplication on Yq11.221 were not inherited from confirmed parents and were therefore presumptively de novo; other events were either inherited or of unknown origin. A 115kb deletion on chromosome 2p16.3 disrupting NRXN1 was found in identical twins concordant for COS. Deletions in NRXN1 have been reported in other patients with schizophrenia (10), mental retardation (19) , and autism (20) . In addition, two COS cases harbored the recurrent microduplication of 500kb on chromosome 16p11.2 that was recently associated with autism and also was detected in two individuals with bipolar disorder (21, 22) . As found with the 16p11.2 duplication in autism (21, 22) , some duplications and deletions in COS patients were inherited from unaffected parents.
Among the 83 individuals with childhood onset schizophrenia, 23 (28%) harbored one or more rare structural variants that deleted or duplicated genes; four individuals carried more than one such event (table S3) . Among the 77 controls constructed from non-transmitted chromosomes of the COS cases' parents, ten (13%) carried such variants. As for the original series, individuals with schizophrenia were significantly more likely than controls to harbor rare structural variants that impacted genes (Table 1 , P = 0.03). The proportion of controls harboring a rare deletion or duplication was higher in the COS series than in the original series. Schizophrenia of very young onset is associated with more severe family history than is schizophrenia of older onset (14) , so parents of COS cases are likely to harbor more genomic lesions related to mental illness than persons from the general population. The use of non-transmitted parental chromosomes as controls is therefore likely to be very conservative. Deletions and duplications in COS cases and their parents were screened using different platforms than were the original series of cases and controls, but within each series, screening was the same for cases and controls. Definitions and sizes of CNVs are not yet identical across platforms (13) .
Structural mutations that disrupt genes (rather than deleting or duplicating entire genes) may be especially likely to have biological consequences. Gene disruptions include premature truncation, internal deletion, gene fusion, or disruption of regulatory or promoter elements (23) . Therefore, in our original series, we determined the breakpoints of genomic deletions and duplications in cases and controls by high-density microarray analysis and genomic sequencing (12) . Genes disrupted by the breakpoints of each event were identified (Table 2) . Individuals with schizophrenia were significantly more likely than controls to harbor rare structural variants that directly disrupted one or more genes (Table 1 ).
Virtually every rare structural mutation detected in our original series was different. Some deletions and duplications were multiple megabases in size; other variants impacted only one or a few genes. Some events in unrelated patients impacted the same genes, but with subtly different genomic breakpoints. For example, similar structural variants on chromosome 18p11 disrupted genes LAMA1 and PTPRM in a case in the original series (Table 2 ) and in a case with childhood onset schizophrenia (table S3) .
Next, we assessed whether the functions of the genes disrupted in cases or controls might be related to schizophrenia. From our original series, for which disrupted genes were fully identified, we compared genes disrupted in cases versus those disrupted in controls using PANTHER (24) and Ingenuity Pathway Analysis (IPA) (25) classification systems. These programs enable one to determine whether an experimentally derived set of genes is over-represented, compared to all known genes (26), in one or more functionally defined pathways. The analyses are undirected; that is, no a priori selection is imposed on the pathways to be queried.
Genes disrupted by structural variants in our series of cases were significantly over-represented in pathways important for brain development, including neuregulin signaling, ERK/MAPK signaling, synaptic long term potentiation, axonal guidance signaling, integrin signaling, and glutamate receptor signaling (Table 3) . Of the 24 genes disrupted by microdeletions or microduplications in cases, eleven genes-ERBB4, MAGI2, DLG2, PRKCD, PRKAG2, PTK2, CAV1, GRM7, SLC1A3, PTPRM, and LAMA1-were components of one or more of these pathways. Genes disrupted in controls were not over-represented in any pathway. It is therefore important that this association was found only for cases and not for controls, was not the result of the larger number of genes disrupted by case events [(12) and table S4], and that enrichment was for signaling pathways particularly involved in brain development.
Mutations in two genes, ERBB4 and SLC1A3, are predicted to have particularly deleterious effects on function. For each of these genes, we experimentally characterized mutant transcripts in the affected individuals. The ERBB4 gene, which encodes a type I transmembrane tyrosine kinase receptor for neuregulins, is disrupted by a 399kb deletion in one case (Fig. 1A) . Using 3' RACE, we determined that the mutant allele produces an alternate transcript in which exons 1-19 are spliced to 198bp of intergenic sequence located downstream of ERBB4 and the deleted genomic region (Fig.  1B) . The alternate transcript is predicted to encode amino acids 1-767 of ERBB4 followed by a novel extension of 15 amino acids, which would result in a protein lacking most of the intracellular kinase domain (Fig. 1C) . The predicted mutant protein is likely to function similarly to an engineered dominant negative ERBB4, DN-ErbB4 (Fig. 1D) , which causes defects in neuronal migration (27) and synaptic neurotransmission (28, 29) .
SLC1A3, a glutamate transporter widely expressed in glial cells, regulates neurotransmitter concentrations at excitatory glutaminergic synapses (30) . Elevated levels of SLC1A3 message have been described in post-mortem thalamus tissue of individuals with schizophrenia (31) . The 503kb deletion in another case disrupts both SLC1A3 and SKP2 and leads to a chimeric transcript expressed in patient lymphoblasts (Fig.  1E) . The predicted fusion protein is likely to differ in expression and function from wildtype SLC1A3.
These genes and nine other genes disrupted by structural variants in cases contribute to cellular signaling networks critical to neuronal cell growth, migration, proliferation, differentiation, apoptosis, and synapse formation (32) . ERBB4 is a receptor for neuregulin (NRG1), and interacts with MAGI2 at neuronal synapses (33) and with DLG2 (34) . The NRG1-ERBB4 complex helps regulate neuronal migration and differentiation, neurotransmitter receptor expression, glial proliferation and synaptic plasticity (35) , and is critical to the development of glutamate networks (28, 29) . GRM7, a G protein-coupled metabotropic glutamate receptor (36) , and SLC1A3, a glutamate transporter (30) , are also involved with glutamate signaling. Glutamate is the primary excitatory neurotransmitter (37) in human brain. Glutamate pathways co-regulate intracellular signaling cascades, including ERK/MAPK (38) , nitric oxide (39) and integrin (40) signaling pathways; all of which play key roles in the orchestration of neurogenesis and neural circuitry (41) (42) (43) . Aberrations of NRG1-ERBB4 pathways and of glutamate neurocircuitry have been implicated previously in schizophrenia. NRG1 is among the best-supported susceptibility genes in association studies of schizophrenia (1) . Variants of ERBB4 and interactions among genes in the NRG1-ERBB signaling pathway have also been associated with the illness (44) (45) (46) .
In two independent cohorts, we found structural variants impacting genes to be more common among individuals with schizophrenia than among controls. Our design does not prove the involvement with the illness of any specific variant, or even the involvement of any specific gene. Rather, these results suggest that schizophrenia can be caused by rare mutations that disrupt genes in pathways of neuronal development and regulation. This model suggests a new approach to gene discovery for schizophrenia, and likely for other psychiatric disorders. Neurodevelopmental pathways involve hundreds of genes. A severe mutation in any one of these genes may lead to a psychopathological phenotype. Furthermore, independent mutations in the same gene or genomic region, such as 16p11.2 or NRXN1, may lead to expression of different neurodevelopmental phenotypes, ranging from schizophrenia to autism to mental retardation (10, (19) (20) (21) or to no clinical manifestation at all. Variable expression may arise by different genetic or epigenetic "second hits" or simply by chance.
Gene discovery efforts should focus on methods that allow detection of structural mutations genome-wide in affected individuals. Any gene harboring a deleterious structural mutation becomes a candidate gene to be screened by other methods for additional, presumably smaller, deleterious mutations in unrelated individuals. This second analytic step would entail complete analysis of variation of a limited number of candidate genes in a very large number of cases and controls. The underlying hypothesis is that a gene harboring one mutation for an illness is likely to harbor more than one. Although each mutation may be individually rare, collectively the total number of disease-causing variants in a gene relevant to the disorder may explain a substantial number of cases. The long-term goals are to identify all genes with mutations leading to the illness and to develop treatment and prevention strategies tailored towards the remediation of the altered pathways. 
